Literature DB >> 23432086

Von Willebrand disease-associated angiodysplasia: a few answers, still many questions.

Massimo Franchini1, Pier Mannuccio Mannucci.   

Abstract

The association between angiodysplasia and von Willebrand disease (VWD) has been known for more than 40 years. Bleeding in the gastrointestinal tract associated with angiodysplasia worsens the clinical course of this inherited haemorrhagic disorder and management may become difficult and challenging. Angiodysplasia associated with acquired defects or dysfunctions of von Willebrand factor (VWF) has also been reported in a variety of conditions such as monoclonal gammopathies, Heyde syndrome and in carriers of ventricular assist devices. The most recent advances concerning the mechanistic, clinical and therapeutic aspects of VWD-associated angiodysplasia are summarized in this review, together with the limitations of our knowledge that warrant further research in the frame of international cooperation.
© 2013 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23432086     DOI: 10.1111/bjh.12272

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  18 in total

1.  Our findings differ.

Authors:  Giuseppe Famularo; Laura Gasbarrone; Giovanni Minisola
Journal:  CMAJ       Date:  2015-10-20       Impact factor: 8.262

Review 2.  Angiodysplasia in von Willebrand Disease: Understanding the Clinical and Basic Science.

Authors:  Soundarya Selvam; Paula James
Journal:  Semin Thromb Hemost       Date:  2017-05-05       Impact factor: 4.180

Review 3.  Coagulopathy in Mechanical Circulatory Support: A Fine Balance.

Authors:  Julie L Rosenthal; Randall C Starling
Journal:  Curr Cardiol Rep       Date:  2015-12       Impact factor: 2.931

Review 4.  Gastrointestinal Bleeding in Native and Prosthetic Valve Disease.

Authors:  Joseph L Blackshear
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-02-03

5.  A Comparative Study of Invasive Modalities for Evaluation of Pulmonary Arteriovenous Fistula after Bidirectional Glenn Shunt.

Authors:  S Viswanatha Kartik; Bijulal Sasidharan; Arun Gopalakrishnan; Harikrishnan K N Kurup; Kavassery Mahadevan Krishnamoorthy; Deepa Sasikumar; Jissa Vinoda Thulaseedharan; Ajitkumar Valaparambil; Jaganmohan Tharakan; Sivasankaran Sivasubramonian
Journal:  Pediatr Cardiol       Date:  2021-07-31       Impact factor: 1.655

Review 6.  von Willebrand factor regulation of blood vessel formation.

Authors:  Anna M Randi; Koval E Smith; Giancarlo Castaman
Journal:  Blood       Date:  2018-06-04       Impact factor: 22.113

7.  Characterization of a Porcine Model for Von Willebrand Disease Type 1 and 3 Regarding Expression of Angiogenic Mediators in the Nonpregnant Female Reproductive Tract.

Authors:  Hanna Allerkamp; Stefanie Lehner; Mahnaz Ekhlasi-Hundrieser; Carsten Detering; Christiane Pfarrer; Mario von Depka Prondzinski
Journal:  Comp Med       Date:  2019-09-16       Impact factor: 0.982

8.  von Willebrand factor is a useful biomarker for liver fibrosis and prediction of hepatocellular carcinoma development in patients with hepatitis B and C.

Authors:  Hiroaki Takaya; Hideto Kawaratani; Yuki Tsuji; Keisuke Nakanishi; Soichiro Saikawa; Shinya Sato; Yasuhiko Sawada; Kosuke Kaji; Yasushi Okura; Naotaka Shimozato; Mitsuteru Kitade; Takemi Akahane; Kei Moriya; Tadashi Namisaki; Akira Mitoro; Masanori Matsumoto; Hiroshi Fukui; Hitoshi Yoshiji
Journal:  United European Gastroenterol J       Date:  2018-05-25       Impact factor: 4.623

9.  On the versatility of von Willebrand factor.

Authors:  Antoine Rauch; Nikolett Wohner; Olivier D Christophe; Cécile V Denis; Sophie Susen; Peter J Lenting
Journal:  Mediterr J Hematol Infect Dis       Date:  2013-07-10       Impact factor: 2.576

Review 10.  A reappraisal of the pharmacologic management of gastrointestinal bleeding in patients with continuous flow left ventricular assist devices.

Authors:  Audrey J Littlefield; Gregory Jones; Alana M Ciolek; Melana Yuzefpolskaya; Douglas L Jennings
Journal:  Heart Fail Rev       Date:  2020-09-01       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.